BME100 f2013:W900 Group3 L1

BME 100 Fall 2013	Home People Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3 Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6 Course Logistics For Instructors Photos Wiki Editing Help
OUR TEAM Name: Marissa Name: Shaun Name: Blake Name: Tony Name: Bryce LAB 1 WRITE-UP Independent and Dependent Variables The Independent Variable: In this experiment, the amount of the drug lipopolysaccharide in (mg) administered to subjects is the independent variable. The Dependent Variable: In this experiment, the increase in the amount of inflammotin protein in the blood (as determined by ELISA assay) of the subjects is the dependent variable. Experimental Design Groups This investigation will utilize 7 groups of participants. Number of subjects per group Each group will consist of 10 subjects, 5 males and 5 females per group. General Protocol The 7 groups will be administered different amounts of lipopolysaccharide. The negative control will be participants with no drug administered, while a positive control will be 12mg of lipopolysaccharide, 120% of the known effective amount. Each group will be administered one of the following doses: Group # Dose 1 0 mg 2 2 mg 3 4 mg 4 6 mg 5 8 mg 6 10 mg 7 12 mg A predetermined amount of blood will be taken and ELISA assay will be run. Then, the drug will be given to the participant, a specific amount of time will be waited and a second blood assay ELISA will be run on a fresh sample to determine the increase in the presence of Inflammotin, if any. The data from all subjects will then be compared to determine the lowest dosage that effects a statistically significant increase in Inflammotin. Subject Selection Our subjects will be selected based on the same age (65 years), the same arbitrarily chosen race (caucasian), and the same current city. Half of our subjects will be male and the other half will be female. Sources of Error and Bias The potential sources of error and bias observed in this experiment include: medical backgrounds of the patients, variations of race and age are not being applied, the amount of funding that the experiment is given, and the genetics of each patient vary. It is unknown if this particular drug requires a prolonged or repeated dosage or what the time table for expected reaction times is. It is also unknown what amount of blood is required to run a successful protein analysis. This leaves a considerable amount of ambiguity in the experimental design.